# ELIOS (NCT03239340)

> A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03239340
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions: Osimertinib
- Enrollment: 154
- Primary outcome: Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 7
- X threads: 3
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=elios-nct03239340

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03239340", "email": "<work email>"}; the inbox owner confirms by the emailed link.